Repros Therapeutics (RPRX +1.7%) provides a clinical update of its Phase 3 DEXA study, saying...


Repros Therapeutics (RPRX +1.7%) provides a clinical update of its Phase 3 DEXA study, saying that recruiting is running better than expected, and that 83% of men with secondary hypogonadism are on target to be successfully treated with no testosterone levels achieved beyond the normal range. Enrollment should ensure mid-2014 NDA submission.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs